Dr. Vineeth Daniel is metabolic disease scientist whose research is focused on the cellular and molecular mechanisms underlying MASLD, liver fibrosis, and T2DM. His research strategically integrates core cell biology, biochemistry, and molecular biology with analyses of clinical samples (serum and tissues) to delineate the pathophysiological mechanisms.
During his Ph.D., he focused on the molecular basis of metabolic dysfunction in MASLD and T2DM, with particular emphasis on glucotoxicity, lead (Pb) toxicity, hepatic lipid dysregulation, protein-protein interactions and transcriptional regulations. During his postdoctoral training, he expanded his research to examine lipotoxic ER stress mediated epigenetic regulation of a DAMP; an extracellular vesicle cargo critical in sterile inflammation and MASH. He further investigated DAMP-mediated hepatic stellate cell activation to understand liver fibrosis. His research has been published in leading peer-reviewed journals. He actively contributes to the scientific community as a peer reviewer for high-impact journals. Dr. Daniel is committed to mentoring students and trainees in rigorous and translational research.
His lab is interested to understand how metabolic stress reshapes liver biology and drives liver fibrosis. He is also interested in deciphering the contribution of adipose tissue dysfunction, independent of obesity, in MASH progression. He also aims to investigate the liver-cardio-renal axis to understand how impaired inter-organ metabolic communication contributes to liver fibrosis and cardio-renal dysfunction.
- D. in Biochemistry (Metabolic Diseases)
Indian Institute of Technology (School of Basic Sciences), Mandi, Himachal Pradesh, India - Sc. in Biotechnology
St. Xavier’s College (University of Mumbai), Mumbai, India - B.Sc. in Biotechnology
SIES College of Arts, Science and Commerce (University of Mumbai), Sion (West), Mumbai, India.
- Postdoctoral Fellow: Epigenetic Regulation in Metabolic Liver Disease (MASH)
Mayo Clinic, Rochester, Minnesota, USA (2022-2025) - Postdoctoral Fellow: Gut-Neural Interaction and Lipid Metabolism
The Scripps Research Institute, La Jolla, California, USA (2022)
- Metabolic dysfunction-associated steatotic liver disease (MASLD/MASH)
- Liver Fibrosis (Hepatic stellate cell biology)
- Type 2 Diabetes Mellitus (T2DM)
- Lipid metabolism and insulin signaling
- ER stress and transcriptional regulation in metabolic disorders
- Exosomal biology and biomarker studies
- Organ cross-talk in metabolic disease (liver-cardiac and liver-renal axis)
- Daniel PV, Erickson HL, Choi D, Hamdan FH, Nakao Y, Puri G, Nishihara T, Yoon Y, Mauer AS, Dasgupta D, Thompson J, Revzin A, Malhi H*, ER stress upregulates S100A11 in steatohepatitis models via epigenetic modifications within the lipotoxicity influenced enhancer, J Clin Invest, 2025 Sep, DOI: 1172/JCI191074.
- Daniel PV#, Puri G#, Luo Y#, Golla N, Nishihara T, Erickson H, Marek G, Kengunte Nagaraj N, Povero D, Mauer AS, Liu J, Malhi H*. Silencing of S100A11 attenuates murine metabolic dysfunction-associated steatohepatitis. NPJ Gut Liver. Dec 2025;2(1):32. doi: 1038/s44355-025-00044-w
- Daniel PV, Malhi H*, Foreseeing Alcohol-Associated Liver Disease through Proteomic Biomarkers, Clin Chem., 2023 Apr, DOI: 1093/clinchem/hvac177
- Daniel PV, Kamthan M, Thakur S, Mondal P*, Molecular pathways dysregulated by Pb2+exposure prompts pancreatic beta-cell dysfunction, Toxicol Res (Oxford), 2022 Jan, DOI: 1093/toxres/tfab121
- Daniel PV, Dogra S, Rawat P, Choubey A, Khan AS, Rajak S, Kamthan M*, Mondal P*, NF-κB p65 regulates hepatic lipogenesis by promoting the nuclear entry of ChREBP in response to a high carbohydrate diet, J Biol Chem., 2021 Apr, DOI: 1016/j.jbc.2021.100714
- Daniel PV*, Mondal P*, Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders, Eur J Cell Biol., 2020 Nov, DOI: 1016/j.ejcb.2020.151128
- Daniel PV$, Kamthan M$, Gera R, Ghosh D, Mondal P*, Chronic exposure to Pb2+ perturbs ChREBP transactivation and coerces hepatic dyslipidemia, FEBS Lett., 2019 Nov, DOI: 1002/1873- 3468.13538
Collaborative:
- Parthasarathy G, Venkatesan N, Sidhu GS, Song MJ, Liao CY, Barrow F, Mauer A, Sehrawat T, Nakao Y, Daniel PV, Dasgupta D, Pavelko K, Revelo XS, Malhi H*, Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH, Hepatol Commun., 2025 Feb, DOI: 1097/HC9.0000000000000613
- Parthasarathy G, Mauer AS, Golla N, Daniel PV, Kim LH, Sidhu GS, Marek GW 3rd, Loeuillard E, Krishnan A, Lee HSK, Pavelko KD, Charlton M, Hirsova P, Ilyas SI, Malhi H*, Macrophage RAGE activation is proinflammatory in NASH, JCI Insight, 2024 Feb, DOI: 1172/jci.insight.169138
- Liu Y*, Zhao Y, Liu Q, Li B, Daniel PV, Chen B, Wu Z, Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis, J Lipid Res., 2024 Jan, DOI:1016/j.jlr.2023.100483.
- Dogra S, Das D, Maity SK, Paul A, Rawat P, Daniel PV, Das K, Mitra S, Chakrabarti P, Mondal P*, Liver-Derived S100A6 Propels β-Cell Dysfunction in NAFLD, Diabetes, 2022 Nov, DOI: 2337/db22-0056
- Dogra S, Kar AK, Girdhar K, Daniel PV, Chatterjee S, Choubey A, Ghosh S, Patnaik S, Ghosh D*, Mondal P*, Zinc oxide nanoparticles attenuate hepatic steatosis development in high-fat-diet fed mice through activated AMPK signaling axis, Nanomedicine: Nanotechnology, Biology and Medicine, 2019 Apr, DOI: 1016/j.nano.2019.01.013.
- Dey G, Singh V, Dewangan J, Daniel PV, Kamthan M, Ghosh D*, Mondal P*, Ghosh S*, Renal Clearable New NIR Probe: Precise Quantification of Albumin in Biofluids and Fatty Liver Disease State Identification through Tissue-Specific High Contrast Imaging in Vivo, ACS Anal Chem., 2017 Oct, DOI: 10.1021/acs.analchem.7b02187
- AASLD Foundation Fellow Research Award - The Liver Meeting 2024
- Outstanding Research Fellow Award, Department of Medicine, Mayo Clinic
- American Liver Foundation Postdoctoral Fellowship
- CSIR-Direct Senior Research Fellowship (SRF)
